MindWalk Develops HYFT Technology to Identify Functional Adjacency in Therapeutic Molecules.

MindWalk Holdings Corp. applies its HYFT technology to detect functional adjacency in AI-designed therapeutics, a source of competitive and valuation risk in drug discovery that sequence-alignment-based analysis often fails to capture. The technology identifies a shared biological "signature" in influenza that remains consistent despite genetic code changes. This supports MindWalk's approach to designing vaccine targets and demonstrates how HYFT identifies meaningful similarities in biology even when molecules appear unrelated at first glance. Functional adjacency is now considered a significant risk in pharmaceutical R&D, and HYFT aims to help identify this convergence early by evaluating similarity at the functional level.